Our Philosophy

ECG is committed to the success of the clients we serve. We view ourselves as a business partner. ECG brings expertise that can expand capability and resolve challenges that threaten to increase capital consumption or compromise financial results. Our approach is informed by a rich understanding of the intricacies of the medical products industry. Our experience provides us with a broad 360° range of solutions to your operational problems.

Partners

Carol Nast
President and Partner, ECG
Email: cnast@enterprisecatalyst.com

Areas of Expertise:

• Manufacturing strategies and establishment or enhancement of manufacturing and quality operations
• Product development and commercialization processes and systems
• Project Management for development, manufacture and commercial launch
• Outsourcing and management of contract manufacturers
• Interim management for operations
• Quality Systems
• Design Control
• Supply Chain Management

Ms. Nast’s experience includes working with companies in pharmaceuticals, biotechnology, medical device and diagnostics and genomics sector. Her focus is the commercialization of new medical products and the enhancement of manufacturing and quality operations. She has led over 50 teams focused on new product commercialization and has been responsible for the commercial launch of over 200 new medical products. She is a recognized expert in outsourcing and management of contract manufacturers.

Prior to joining ECG, Ms Nast was Chief Operating Officer at NuGEN Technologies, Vice President of Device Manufacturing for Nektar (formerly Inhale Therapeutics), and ran manufacturing plants for Syva ( a division of Syntex Pharmaceuticals), BioRad and Warner Lambert. Ms Nast holds an MS in Biochemistry and Medical Technology from Texas Christian University and is a graduate of the Executive Business Program at Stanford University.

Deborah Wright
Director and Partner, ECG
Email: dwright@enterprisecatalyst.com

Areas of Expertise:

• Manufacturing strategies and establishment or enhancement of manufacturing and quality operations
• Process development and commercialization processes and systems
• Project Management for development, manufacture and commercial launch
• Outsourcing and management of contract manufacturers
• Process validation including software
• Quality Systems
• Supply Chain Management

Ms. Wright’s experience includes working with companies in the biotechnology, medical device, diagnostics and genomics sectors. Her focus is process engineering and optimization, validation and data management systems and commercialization of new medical products. She has established manufacturing and quality control processes for new technologies within large companies as well as small start-ups. She has participated in or led activities leading to commercial launch of over 100 products.

Prior to joining ECG, Ms Wright was Vice President of Operations for Cepheid, and ran manufacturing and quality systems operations for BioRad and Syva (a division of Syntex Pharmaceuticals). She has extensive project management experience with new product introduction for all regulatory levels of diagnostic products. Ms Wright holds a BS in Biology from the University of California at San Diego.

Terence D. Boardman, PhD.
Partner, ECG
Email: tboardman@enterprisecatalyst.com

Areas of Expertise:

• Manufacturing Strategies
• Outsourcing Strategies
• Drug–Device Combination Products
• Technology Transfer
• Product and Process Development
• Due Diligence
• Logistics
• Interim Management

Dr Boardman’s experience spans both large pharmaceutical organizations as well as startup biotechnology companies. His focus is the development and commercialization of both drug and drug/device combination products.

Dr Boardman has been responsible for the development and ultimate partnership of a number of pharmaceutical products that culminated in the successful launch and generation of significant product revenues. He has developed manufacturing and outsourcing strategies for emerging pharmaceutical companies, as well as identifying in-licensing opportunities for a number of specialty pharmaceutical companies.

Prior to joining ECG Dr Boardman was Vice President Operations for Sequential Inc a specialty pharmaceutical company, and Vice President of Process Development and Manufacturing for Nektar Therapeutics (formerly Inhale Therapeutics, Inc.)

Before coming to the US and joining Nektar, Dr Boardman was Managing Director of CCL Pharmaceuticals, one of the largest contract pharmaceutical manufacturers in the UK.

Dr. Boardman has also held a variety of senior scientific and management positions within Fisons Pharmaceuticals (now Sanofi-Aventis), which encompassed development, technical and operational roles. He holds a Ph.D. in Biochemical Engineering from the University of Manchester , an MSc from the University of Leeds and is a Fellow of the Institution of Chemical Engineers.

Stephen L. Hurst , JD
Partner, ECG
Email: shurst@enterprisecatalyst.com

Areas of Expertise:

• Interim executive management, including chief executive officer, chief operating officer and executive vice president
• Mergers and acquisitions with particular emphasis on technology and product acquisitions
• Pharmaceutical development partnerships with demonstrated success in negotiating long-term, profitable relationships between biotech and pharma companies
• Strategic business planning focused on integrated IP, product development and business plans
• Public and private equity and debt financings, including seed and venture financing, IPOs, secondary offerings, convertible debt and PIPEs
• Global health policy focused on market-based incentives for vaccine and drug development

Mr. Hurst has more than twenty year’s experience in the biopharmaceutical industry, dividing his time between business and management consulting and a variety of senior executive positions. Serving as a biopharmaceutical industry expert, he recently advised the G7/G8 governments on global health policy initiatives.

He was President and CEO of Sequential, Inc., a development-stage oncology company. Prior to that he was Executive Vice President at Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.) and held several other key positions, including General Counsel & Secretary, interim Senior Vice President of Operations, Vice President of Intellectual Property and Licensing and Head of Business Development.

He was responsible for university-industry relationships as the first Campus Patent Coordinator at the University of California , San Francisco and served as legal counsel to the 1990 International AIDS Meeting. Mr. Hurst worked as a patent attorney specializing in biotechnology and held a variety of research positions at the Lawrence Berkeley National Laboratory, Division of Biology and Medicine and the University of California , San Francisco , Department of Radiation Oncology and the Brain Tumor Research Center in the fields of radiobiology, cancer biology, medical physics and biophysics.